Presentation is loading. Please wait.

Presentation is loading. Please wait.

Vaccine Development and India Dr. Tarit K. Mukhopadhyay Dept. of Biochemical Engineering, UCL.

Similar presentations


Presentation on theme: "Vaccine Development and India Dr. Tarit K. Mukhopadhyay Dept. of Biochemical Engineering, UCL."— Presentation transcript:

1 Vaccine Development and India Dr. Tarit K. Mukhopadhyay Dept. of Biochemical Engineering, UCL

2 Historical Perspective (1980) ProductPublic SectorPrivate Sector DTP$0.15$0.30 OPV$0.35$1.60 MMR$2.71$7.24 Source: United States CDC, 2001

3 Historical Perspective (2000) ProductPublic SectorPrivate Sector DTaP$9.25$16.64 IPV$6.99$15.42 MMR$14.69$28.19 Varicella$35.41$45.56 Source: United States CDC, 2001

4 The Vaccine Market

5 Vaccine Manufacture in India Very active One out of every two children in the world is immunized by a vaccine made by the Serum Institute of India Primarily motivated through cost savings of production Manufacture old vaccines, less profitable, but no IP That landscape is changing with MNC / Public Institutions collaborating with Indian companies – facilitating tech transfer

6 Technology transfer - Transferring MNC Expand market base Increase manufacturing capacity Additional regulatory pathway Public Institutions Provide access to manufacturing process Specialist knowledge

7 Technology transfer - Receiving 22% pipeline products with MNC Fill bulk Restrictive market access 70% pipeline products with academic and public research institutions Better equity of benefits Full knowledge transfer

8 Impact on Hib-vaccines Bulk importPartnershipLicense new product technology Market control by recipient Limited to local market Negotiated, but often limited to local None, based on royalty payment Ability to pass on technology NonePossible to sell bulk, advice Yes Independent production Little or noneYes, conditionalYes ExamplesBharat and Pfizer, Panacea and Novartis Serum Inst. with MVP (Men A), Biological E and NVI Several with NIH

9 Companies of Note Bharat Biotech Int. Contract with Pfizer for Hib NIH (US) license agreement for rotavirus HepB vaccine patent Biological E Working with NVI to develop new Hib combination vaccine Collaborate with small biotechs, divide profits and global market share

10 Companies of Note Panacea Biotec Experienced IP management DTP-HepB-Hib combination vaccine with Novartis V&D Serum Institute of India Avoids MNC - Past work based on scale up Focus more on PPP Meningitis Vaccine Project (MenA) WHO (aerosol measles vaccine)

11 Cost based analysis of manufacture (2010) SynCo BioSerum Institute of India less 0.50c/dose MVP FDA WHO - Regulatory Pathway

12 Shifting Disease Profile

13 Neglected Diseases

14 Primary Funders

15 Final Remarks Historically, India focused on less innovative, old off patent vaccines Highly trained persons capable of licensing in new technology Converging markets due to shifting disease profile Opportunities to collaborate and gain on cost reduction strategies More competition – cheaper healthcare for all?


Download ppt "Vaccine Development and India Dr. Tarit K. Mukhopadhyay Dept. of Biochemical Engineering, UCL."

Similar presentations


Ads by Google